Biorce is a Barcelona-based healthtech company building AI-native infrastructure for clinical trials. Its core product, Aika, helps pharmaceutical companies, biotechs and CROs design regulator-ready trial protocols in roughly 90 seconds, drawing on a corpus of more than one million clinical studies and 260,000+ protocols. By cutting protocol design time by at least 50% and flagging regulatory and feasibility risks early, Biorce aims to compress the years and billions of dollars it takes to bring a drug to market - so treatments reach patients sooner. In February 2026 it closed a USD $52.5M Series A led by DST Global, the largest Series A to date in the Iberian healthtech and AI ecosystem.
ClinChoice is a mid-size, global, full-service contract research organization (CRO) that helps pharmaceutical, biotech, medical device, and consumer health companies run clinical trials and bring drugs and devices to market. Founded in 1995 and headquartered in Horsham, Pennsylvania, the firm employs roughly 4,000 people across the Americas, Europe, and Asia-Pacific, offering clinical development, biometrics, safety/pharmacovigilance, regulatory affairs, post-marketing real-world evidence, and technology services. After rebranding from Fountain Medical Development (FMD K&L) in 2020 and raising a $150M Series E in 2022, ClinChoice has grown through acquisitions to serve six of the top ten pharma companies while focusing on emerging and mid-size biotech innovators.
Elysium Health is a New York-based cellular health company that turns peer-reviewed aging research into consumer products. Founded in 2014 by entrepreneur Eric Marcotulli, operator Dan Alminana, and MIT aging biologist Leonard Guarente, it pairs a scientific advisory board stacked with Nobel laureates with a direct-to-consumer model. Its flagship supplement Basis raises NAD+ levels tied to cellular energy, and its Index test estimates biological age from a saliva sample using epigenetic methylation analysis.
Nilo Therapeutics is a New York-based biotechnology company developing a new class of medicines that target the brain-body neural circuits regulating the immune system. Building on discoveries that identified specific vagal neurons controlling systemic inflammation, Nilo aims to restore immune homeostasis centrally rather than broadly suppress the immune system, offering a differentiated approach to treating autoimmune and inflammatory disease. The company launched out of stealth in October 2025 with a $101 million Series A.
Noveome Biotherapeutics is a Pittsburgh clinical-stage biopharmaceutical company built around ST266, a multi-targeted secretome of hundreds of biologically active proteins harvested from a novel population of amnion-derived cells. Rather than transplanting cells, Noveome delivers the healing signals those cells secrete - aiming to modulate inflammation, protect nerves, and accelerate tissue repair. Its lead program treats necrotizing enterocolitis, a devastating gut disease in premature infants, with additional pipeline work spanning ophthalmology, neurology, and dermatology.
Pleno Inc. is a San Diego multi-omic instrument company rebuilding the economics of biological target detection. Its RAPTOR platform, powered by proprietary Hypercoding technology borrowed from telecommunications signal processing, can detect up to 10,000 targets in a single sample at PCR-like speed and cost. Founded by serial entrepreneur Pieter van Rooyen, the company is moving from R&D into commercial launch with backing from Deerfield Management and Foresite Capital.
Zafrens is a San Diego biotechnology company building an ultra-high-throughput single-cell platform that isolates, images, runs assays on, and sequences millions of individual cells per day. Its Z-Screen technology swaps the conventional 96-well plate for a credit-card-sized plastic chip holding 50,000 to 200,000 microwells, each with integrated imaging and multi-omic sequencing. By linking perturbation to genotype, phenotype and function at single-cell resolution, Zafrens compresses multiple stages of drug discovery into a single benchtop experiment - a 500x to 2,000x jump in the number of experiments a scientist can run at one timepoint.
Paradigm4 builds scientific data management and analytics software for the life sciences. Its flagship REVEAL platform and SciDB array database let pharma, biotech, and research institutions integrate and analyze massive multimodal datasets - genomics, multi-omics, imaging, clinical records, wearables, and environmental data - to find biomarkers and validate drug targets. Co-founded in 2010 by entrepreneur Marilyn Matz and Turing Award-winning MIT professor Michael Stonebraker, the company is based in Waltham, Massachusetts.
Watershed Bio (legally Watershed Informatics) is a Cambridge, Massachusetts startup building a unified, cloud-based platform for biological data analysis. Its product, Omics Bench, lets biologists and bioinformaticians securely store, harmonize, and analyze multi-omic data - genomics, single-cell and spatial transcriptomics, epigenomics, proteomics, metabolomics, microbial sequencing and protein folding - using customizable and AI-assisted workflows backed by elastic supercomputing. The pitch: go from sample to therapeutic insight in a single day instead of weeks, closing the gap between high-code and no-code bioinformatics for drug-discovery teams.
Peter DiLaura is the CEO and Board Director of Helicore Biopharma, a San Mateo biotech building long-acting antibody-peptide conjugates that go after obesity by neutralizing the GIP hormone in the bloodstream rather than blocking its receptor. With nearly three decades of company-building behind him - CEO roles at Initial Therapeutics and Second Genome, business and strategy chief at Sonoma Biotherapeutics, and time as an Entrepreneur-in-Residence at Third Rock Ventures - he is the operator brought in to turn a $65M Series A and a clinic-ready antibody into medicines that aim for quarterly dosing and better-quality weight loss.
Curavit Clinical Research is a Boston-based, all-virtual Contract Research Organization (CRO) that designs and runs decentralized clinical trials. Through its Virtual Clinical Site and STRATUS platform, Curavit recruits, enrolls, and monitors diverse patient populations remotely - eliminating physical site infrastructure and travel while improving data quality. The company specializes in trials for digital therapeutics (DTx) and partners with sponsors and existing CROs to fix the execution layer of clinical research, accelerating timelines and lowering costs.
Mohit Rawat is the Boston-based CEO of Myricx Bio, a UK-US biotech building a first-in-class antibody-drug conjugate platform based on NMT inhibition to treat cancer. He arrived in September 2025 fresh off Fusion Pharmaceuticals' $2.4 billion sale to AstraZeneca, where he was President and Chief Business Officer. With a Harvard MBA, an MIT chemical engineering master's, and stints at Novartis, AbbVie and McKinsey, he is steering Myricx toward its first human clinical trials in 2026.
Benchling is a cloud platform built for biotech R&D - a single, biology-first system of record where scientists design experiments, track samples, manage molecular data, and collaborate. Founded in 2012 out of MIT, it has grown into the operating system for modern life science, used by hundreds of thousands of scientists at companies ranging from startups to the largest biopharma firms, and is now embedding AI agents and predictive models directly into the lab workflow.
Rudolph and Sletten is a California-based general contractor that has built much of Silicon Valley's physical fabric - from Apple Park and Lucasfilm's Skywalker Ranch to hospitals, research labs and university campuses. Founded in 1959 in a Los Altos garage, the firm pioneered guaranteed-maximum-price, fast-track delivery and grew into one of the West Coast's largest builders of technically complex healthcare, life-sciences and education projects. Now a subsidiary of Tutor Perini, it employs roughly 740 people and reports about $307 million in annual revenue.
Anthony Costello is the CEO of Medidata Solutions, a Dassault Systèmes company, and one of clinical research technology's most seasoned architects. With nearly 30 years in the field, he started as a data manager at Genentech, co-founded two companies (Nextrials and Mytrus), and was acquired by Medidata before rising to lead it. Today he oversees over 8,000 active clinical studies globally each year, championing AI-driven trial innovation, decentralized models, and patient-centric design at the White House Clinical Trials Forum and beyond.
Abhishek Jha is the Co-Founder and CEO of Elucidata, a San Francisco-based AI company making biomedical data AI-ready for drug discovery and pharmaceutical R&D. A trained physical chemist with a PhD from the University of Chicago and postdoctoral work at MIT, he spent years at Agios Pharmaceuticals contributing to four FDA-approved first-in-class therapies before co-founding Elucidata in 2015. Under his leadership, the company has raised over $22.7M in funding, grown to 170 employees, and achieved $22.2M ARR, while evolving from a data-curation platform into an AI company solving out-of-distribution (OOD) problems in biomedical research - work that earned Elucidata recognition as one of Fast Company's Most Innovative Companies in 2024.
Viz.ai is an AI-powered care coordination platform trusted by over 2,000 hospitals across the United States. The company's suite of 50+ FDA-cleared algorithms analyzes medical imaging data in real time - detecting strokes, brain hemorrhages, aneurysms, pulmonary embolisms, and cardiac conditions - then instantly alerts the right clinical team so treatment can begin minutes faster. Founded in 2016 by neurosurgeon Dr. Chris Mansi and machine learning researcher Dr. David Golan, Viz.ai has grown into a platform covering 230 million lives, supporting 70,000+ healthcare providers, and partnering with 14+ leading pharmaceutical companies to accelerate drug development and patient access.
Arthur T. Sands, M.D., Ph.D., is the President and CEO of Nurix Therapeutics, a clinical-stage biopharmaceutical company pioneering targeted protein degradation medicines. A co-founder of Lexicon Pharmaceuticals in 1995, he spent 19 years transforming that company from a research startup into a drug-development enterprise generating over $450 million in revenue. At Nurix, he leads efforts to deploy a proprietary DEL-AI platform - combining DNA-encoded libraries with machine learning - to discover and develop small-molecule degraders and degrader-antibody conjugates for cancer and inflammatory diseases. The company's lead asset, bexobrutideg (a BTK degrader), entered pivotal Phase 2 development in 2025 with an 83% objective response rate in relapsed CLL patients.
Dr. Dino Dina is a Genoa-born physician-scientist who spent 15 years building Dynavax Technologies as its President and CEO, shepherding the company through the long road toward HEPLISAV-B, a two-dose hepatitis B vaccine whose CpG 1018 adjuvant technology later became a cornerstone of global COVID-19 vaccine programs. Before Dynavax, he built the Vaccine Group at Chiron Corporation and led Chiron Vaccines to the first-ever approval of an adjuvanted influenza vaccine in Italy. Since retiring in 2013, he has poured equal scientific rigor into his Cimarossa estate on Howell Mountain, Napa Valley - 60 mountain acres of vines and 1,200 olive trees named for the Italian phrase meaning 'red hilltop.'
Joe Belanoff is the co-founder and CEO of Corcept Therapeutics, a Redwood City-based biopharmaceutical company he has led since 1999. A physician-scientist trained at Amherst College, Columbia University, and Stanford, Belanoff pivoted from academia to entrepreneurship after co-developing intellectual property on cortisol modulation with Stanford psychiatry chair Alan Schatzberg. Under his leadership, Corcept achieved two landmark FDA approvals: Korlym in 2012 for Cushing's syndrome and Lifyorli in 2026 for platinum-resistant ovarian cancer - the first selective glucocorticoid receptor antagonist ever approved. He maintains an adjunct professorship at Stanford while steering a company with over $760 million in annual revenue and more than 30 ongoing clinical studies.
John McCutcheon is President, CEO, and Director of EBR Systems, Inc., the Sunnyvale-based medical device company behind the WiSE CRT system - the world's first FDA-approved leadless solution for left ventricular pacing. With over 40 years in medical device sales, marketing, and general management, McCutcheon has shepherded EBR through pivotal clinical trials, FDA Breakthrough Device Designation, and the landmark FDA approval in April 2025. Before EBR, he led Ceterix Orthopaedics to a $105 million acquisition by Smith & Nephew. He brings a track record of building and selling medical device companies, now steering EBR's commercial launch of a technology that could transform how heart failure patients receive cardiac resynchronization therapy.
Kedar Relangi is the CEO and co-founder of Wilco Source, a Santa Clara-based Salesforce consulting firm specializing in healthcare and life sciences. Founded in 2014 alongside Sundar Ramasamy, Wilco Source became a go-to partner for pharmaceutical companies, medical device firms, payers, and health providers seeking enterprise-wide Salesforce implementations. In November 2022, CitiusTech acquired Wilco Source in a strategic move to combine healthcare domain depth with specialized Salesforce delivery capabilities. With a background spanning computer science degrees from Osmania University and RWTH Aachen, and over 17 years in IT and healthcare technology, Relangi built Wilco Source into a ~440-person organization with roughly $55M in annual revenue before the acquisition.
Margo Georgiadis is CEO-Partner at Flagship Pioneering and co-founder & CEO of Montai Therapeutics, a biotech company using AI to discover drugs from natural compounds humans have consumed for centuries. A Harvard double-alumna (Phi Beta Kappa undergrad, Baker Scholar MBA), she has reinvented herself across industries - from McKinsey partner to Google Americas President, Mattel CEO, Ancestry.com CEO (overseeing its $5B sale to Blackstone), and now biotech pioneer building a platform that turns ancient botanicals and foods into precision medicines for chronic disease.
Michael F. Bigham is a veteran biopharmaceutical executive and investor who spent nearly a decade as Chairman and CEO of Paratek Pharmaceuticals, guiding the company through the FDA approval and commercial launch of NUZYRA (omadacycline) - a novel tetracycline-class antibiotic tackling drug-resistant bacterial infections. A Stanford MBA and CPA with roots in Gilead Sciences' early days, he has built, funded, and led companies across the full arc of drug development. He now operates as founder and managing director of Firebrand River Capital.
Pat Cotroneo is a seasoned life sciences financial executive who spent over two decades at FibroGen, Inc. (now Kyntra Bio), serving as Chief Financial Officer from 2008 to 2021. During his tenure, he guided FibroGen through two defining transformations: its landmark 2014 IPO - the largest biotech public offering in 12 years - and its evolution into a commercial-stage company with the launch of roxadustat in China in 2019. With 25+ years of senior financial leadership in life sciences, Cotroneo built his career at Deloitte & Touche, SyStemix (a Novartis subsidiary), and ultimately FibroGen, where he oversaw finance, accounting, human resources, and information technology before transitioning to Executive Advisor to the CEO.
Alec Ford is the chief executive of Karius, a Redwood City genomics-diagnostics company that reads microbial cell-free DNA from a single tube of blood to identify more than a thousand pathogens. He took the job in October 2020 and led the company through a $100M Series C in May 2024.
Dr. Siva Samy is the founder, CEO, and Chief Product Strategist of ValGenesis, the global leader in digital validation lifecycle management for the life sciences industry. He built the first platform to fully digitize and automate the pharmaceutical validation process - the compliance-critical system that ensures every drug, device, and biotech product is manufactured correctly. Under his leadership, ValGenesis has become trusted by 30 of the top 50 global life sciences companies and has raised over $40 million in funding, including a $24M investment from Morgan Stanley Expansion Capital and a $16M debt financing in 2025.
Steven Basta is the President and CEO of Phathom Pharmaceuticals (NASDAQ: PHAT), a commercial-stage biopharmaceutical company focused on gastrointestinal disorders. He joined in April 2025 to lead the commercialization of VOQUEZNA (vonoprazan), a next-generation potassium-competitive acid blocker for GERD and H. pylori. With more than 25 years of biopharma and medical device leadership spanning BioForm Medical, Merz Aesthetics, AlterG, Menlo Therapeutics, Mahana Therapeutics, and SaNOtize, Basta brings a track record of building and launching products in highly competitive markets. He trained as a biomedical engineer at Johns Hopkins and later earned his MBA from Northwestern's Kellogg School.